ChemoCentryx (CCXI) Tops Q3 EPS by 13c

ChemoCentryx (NASDAQ: CCXI) reported Q3 EPS of ($0.32), $0.13 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13.48 million.

For earnings history and earnings-related data on ChemoCentryx (CCXI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M